Author

Joan C. Smith

Google (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Jason M. SheltzeriD· 2 shared Aditi Swamy· 1 shared Adrian R. KraineriD· 1 shared Anand VasudevaniD· 1 shared Andrew Chatr‐aryamontriiD· 1 shared Armin C. BrauniD· 1 shared Brianna E. MendelsoniD· 1 shared Claudio Chuaqui· 1 shared

Activity by Year

2021-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jason M. SheltzerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions

Linda Julian, Lisa Crozier, Devon A. Lukow, Sanat Mishra, Aditi Swamy, Ryan A. Hagenson, Peter C. Sennhenn, Erin L. Sausville, Brianna E. Mendelson, Claudio Chuaqui, Lu Qiao, Anand Vasudevan, Kuan‐Ting Lin, Sonam Bhatia, Thierry Bertomeu, , Jason M. Sheltzer

This study shows CDK11 is critical for cancer cell survival and identifies 1p36 deletions as a biomarker for CDK11 inhibitor sensitivity, but on-target toxicity limits therapeutic efficacy.

bioRxiv · Aug 3, 2025 · PreprintCancer Biology

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Markus Hoffmann, Heike Hofmann-Winkler, Joan C. Smith, Nadine Krüger, Prerna Arora, Lambert K. Sørensen, Ole Schmeltz Søgaard, Jørgen Bo Hasselstrøm, Michael Winkler, Tim Hempel, Lluı́s Raich, Simon Olsson, Olga Danov, Danny David Jonigk, Takashi Yamazoe, , Stefan Pöhlmann

This study shows camostat mesylate inhibits SARS-CoV-2 by blocking TMPRSS2 and its metabolite GBPA also has antiviral activity, suggesting no resistance through TMPRSS2-related proteases.

EBioMedicine · Mar 1, 2021Peer-reviewedMolecular Biology